Oxaliplatin as a radiosensitizing agent in rectal cancer

ArticleinAnti-cancer drugs 22(4):317-23 · April 2011with1 Read
Impact Factor: 1.78 · DOI: 10.1097/CAD.0b013e328343e076 · Source: PubMed

    Abstract

    The efficacy of oxaliplatin monotherapy against several solid tumors and its relative lack of nephrotoxicity and myelosupression, coupled with results of the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer trial, led to a great deal of interest for the implementation of this chemotherapeutic agent in the preoperative setting for the management of adenocarcinoma of the rectum. Despite limited in-vitro and in-vivo data with regard to the radiosensitizing properties of oxaliplatin in rectal cancer, it rapidly entered phase I-III clinical trials. This study reviews the results of these trials and the current status of oxaliplatin as a radiosensitizing agent in the neoadjuvant management of rectal cancer.